|
1
|
Bowen MA, Patel DD, Li X, Modrell B,
Malacko AR, Wang WC, Marquardt H, Neubauer M, Pesando JM, Francke
U, et al: Cloning, mapping and characterization of activated
leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med.
181:2213–2220. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Patel DD, Wee SF, Whichard LP, Bowen MA,
Pesando JM, Aruffo A and Haynes BF: Identification and
characterization of a 100-kD ligand for CD6 on human thymic
epithelial cells. J Exp Med. 181:1563–1568. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hansen AG, Arnold SA, Jiang M, Palmer TD,
Ketova T, Merkel A, Pickup M, Samaras S, Shyr Y, Moses HL, et al:
ALCAM/CD166 is a TGF-β-responsive marker and functional regulator
of prostate cancer metastasis to bone. Cancer Res. 74:1404–1415.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hong X, Michalski CW, Kong B, Zhang W,
Raggi MC, Sauliunaite D, De Oliveira T, Friess H and Kleeff J:
ALCAM is associated with chemoresistance and tumor cell adhesion in
pancreatic cancer. J Surg Oncol. 101:564–569. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kozovska Z, Gabrisova V and Kucerova L:
Colon cancer: Cancer stem cells markers, drug resistance and
treatment. Biomed Pharmacother. 68:911–916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Penna E, Orso F, Cimino D, Vercellino I,
Grassi E, Quaglino E, Turco E and Taverna D: miR-214 coordinates
melanoma progression by upregulating ALCAM through TFAP2 and
miR-148b downmodulation. Cancer Res. 73:4098–4111. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Piao D, Jiang T, Liu G, Wang B, Xu J and
Zhu A: Clinical implications of activated leukocyte cell adhesion
molecule expression in breast cancer. Mol Biol Rep. 39:661–668.
2012. View Article : Google Scholar
|
|
8
|
Tachezy M, Zander H, Wolters-Eisfeld G,
Müller J, Wicklein D, Gebauer F, Izbicki JR and Bockhorn M:
Activated leukocyte cell adhesion molecule (CD166): An 'inert'
cancer stem cell marker for non-small cell lung cancer? Stem Cells.
32:1429–1436. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ye M, Du YL, Nie YQ, Zhou ZW, Cao J and Li
YF: Overexpression of activated leukocute cell adhesion molecule in
gastric cancer is associated with advanced stages and poor
prognosis and miR-9 deregulation. Mol Med Rep. 11:2004–2012.
2015.
|
|
10
|
Yu W, Wang J, Ma L, Tang X, Qiao Y, Pan Q,
Yu Y and Sun F: CD166 plays a pro-carcinogenic role in liver cancer
cells via inhibition of FOXO proteins through AKT. Oncol Rep.
32:677–683. 2014.PubMed/NCBI
|
|
11
|
Zhao Z, Lu P, Zhang H, Xu H, Gao N, Li M
and Liu C: Nestin positively regulates the Wnt/β-catenin pathway
and the proliferation, survival and invasiveness of breast cancer
stem cells. Breast Cancer Res. 16:4082014. View Article : Google Scholar
|
|
12
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rajasekhar VK, Studer L, Gerald W, Socci
ND and Scher HI: Tumour-initiating stem-like cells in human
prostate cancer exhibit increased NF-κB signalling. Nat Commun.
2:1622011. View Article : Google Scholar
|
|
14
|
Jezierska A, Matysiak W and Motyl T:
ALCAM/CD166 protects breast cancer cells against apoptosis and
autophagy. Med Sci Monit. 12:BR263–BR273. 2006.PubMed/NCBI
|
|
15
|
Lunter PC, van Kilsdonk JW, van Beek H,
Cornelissen IM, Bergers M, Willems PH, van Muijen GN and Swart GW:
Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a
novel actor in invasive growth, controls matrix metalloproteinase
activity. Cancer Res. 65:8801–8808. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jezierska A, Olszewski WP, Pietruszkiewicz
J, Olszewski W, Matysiak W and Motyl T: Activated Leukocyte Cell
Adhesion Molecule (ALCAM) is associated with suppression of breast
cancer cells invasion. Med Sci Monit. 12:BR245–BR256.
2006.PubMed/NCBI
|
|
17
|
Fujiwara K, Ohuchida K, Sada M, Horioka K,
Ulrich CD III, Shindo K, Ohtsuka T, Takahata S, Mizumoto K, Oda Y
and Tanaka M: CD166/ALCAM expression is characteristic of
tumorigenicity and invasive and migratory activities of pancreatic
cancer cells. PLoS One. 9:e1072472014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Erkan M, Adler G, Apte MV, Bachem MG,
Buchholz M, Detlefsen S, Esposito I, Friess H, Gress TM, Habisch
HJ, et al: StellaTUM: Current consensus and discussion on
pancreatic stellate cell research. Gut. 61:172–178. 2012.
View Article : Google Scholar
|
|
19
|
Erkan M, Kleeff J, Gorbachevski A, Reiser
C, Mitkus T, Esposito I, Giese T, Büchler MW, Giese NA and Friess
H: Periostin creates a tumor-supportive microenvironment in the
pancreas by sustaining fibrogenic stellate cell activity.
Gastroenterology. 132:1447–1464. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Erkan M, Reiser-Erkan C, Michalski CW,
Deucker S, Sauliunaite D, Streit S, Esposito I, Friess H and Kleeff
J: Cancer-stellate cell interactions perpetuate the
hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma.
Neoplasia. 11:497–508. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang W, Erkan M, Abiatari I, Giese NA,
Felix K, Kayed H, Büchler MW, Friess H and Kleeff J: Expression of
extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) in
pancreatic neoplasm and pancreatic stellate cells. Cancer Biol
Ther. 6:218–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Abiatari I, Esposito I, Oliveira TD, Felix
K, Xin H, Penzel R, Giese T, Friess H and Kleeff J: Moesin
dependent cytoskeleton remodeling is associated with an anaplastic
phenotype of pancreatic cancer. J Cell Mol Med. 14:1166–1179.
2009.
|
|
23
|
Kayed H, Kleeff J, Kolb A, Ketterer K,
Keleg S, Felix K, Giese T, Penzel R, Zentgraf H, Büchler MW, et al:
FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and
influences pancreatic cancer cell growth. Int J Cancer. 118:43–54.
2006. View Article : Google Scholar
|
|
24
|
Erkan M, Kleeff J, Esposito I, Giese T,
Ketterer K, Büchler MW, Giese NA and Friess H: Loss of BNIP3
expression is a late event in pancreatic cancer contributing to
chemoresistance and worsened prognosis. Oncogene. 24:4421–4432.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Behnan J, Isakson P, Joel M, Cilio C,
Langmoen IA, Vik-Mo EO and Badn W: Recruited brain tumor-derived
mesenchymal stem cells contribute to brain tumor progression. Stem
Cells. 32:1110–1123. 2014. View Article : Google Scholar
|
|
26
|
Levesque MC, Heinly CS, Whichard LP and
Patel DD: Cytokine-regulated expression of activated leukocyte cell
adhesion molecule (CD166) on monocyte-lineage cells and in
rheumatoid arthritis synovium. Arthritis Rheum. 41:2221–2229. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Habisch H, Zhou S, Siech M and Bachem MG:
Interaction of stellate cells with pancreatic carcinoma cells.
Cancers (Basel). 2:1661–1682. 2010. View Article : Google Scholar
|
|
28
|
Wilson JS, Pirola RC and Apte MV: Stars
and stripes in pancreatic cancer: Role of stellate cells and stroma
in cancer progression. Front Physiol. 5:522014. View Article : Google Scholar : PubMed/NCBI
|
